BACKGROUND: The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. METHODS: We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4(+) T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. RESULTS: Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4(+) T cell latent reservoir in all 5 infants. CONCLUSIONS: The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.
BACKGROUND: The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. METHODS: We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4(+) T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. RESULTS: Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4(+) T cell latent reservoir in all 5 infants. CONCLUSIONS: The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.
Authors: Deborah Persaud; Paul E Palumbo; Carrie Ziemniak; Michael D Hughes; Carmelita G Alvero; Katherine Luzuriaga; Ram Yogev; Edmund V Capparelli; Ellen G Chadwick Journal: AIDS Date: 2012-07-31 Impact factor: 4.177
Authors: Ellen G Chadwick; Ram Yogev; Carmelita G Alvero; Michael D Hughes; Rohan Hazra; Jorge A Pinto; Brian L Robbins; Barbara E Heckman; Paul E Palumbo; Edmund V Capparelli Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Silvia Bertagnolio; Martina Penazzato; Michael R Jordan; Deborah Persaud; Lynne M Mofenson; Diane E Bennett Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Allison L Agwu; Jennifer Y Chang; Ryan E Wiegand; John T Wheeling; Beverly A Bohannon; Kenneth L Dominguez Journal: AIDS Patient Care STDS Date: 2014-01 Impact factor: 5.078
Authors: Allison Agwu; Jane C Lindsey; Kimberly Ferguson; Haili Zhang; Stephen Spector; Bret J Rudy; Stuart C Ray; Steven D Douglas; Patricia M Flynn; Deborah Persaud Journal: AIDS Patient Care STDS Date: 2008-07 Impact factor: 5.078